Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors

R. E. Schwarz, S. Iwatsuki, R. B. Herberman, T. L. Whiteside

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Adherent lymphokine-activated killer cells (A-LAK cells) obtained from human peripheral blood mononuclear cells represent a population of potent antitumor effectors enriched in interleukin-2(IL-2)-activated natural killer cells. This study shows that A-LAK cells can be successfully generated from the blood of patients with liver cancer not treated with adjuvant chemotherapy or irradiation. Mononuclear cells were isolated from the blood of 33 patients with liver tumors (6 benign, 10 primary malignant, 17 metastatic) at the time of liver resection. A-LAK cells were separated by adherence to plastic following activation of peripheral blood mononuclear cells in 1000 U/ml recombinant IL-2. A-LAK cells (enriched up to 92% in CD3-CD56+ cells) showed better subsequent expansion and two to six times higher antitumor cytotoxicity per cell than unseparated LAK cells cultured under the same conditions. The ability to generate A-LAK cells with superior in vitro cytotoxicity from the blood of most patients with liver cancer indicates that adoptive cellular immunotherapy may be a feasible and new way of treatment for primary and secondary hepatic neoplasms in man.

Original languageEnglish (US)
Pages (from-to)312-316
Number of pages5
JournalCancer Immunology Immunotherapy
Volume30
Issue number5
DOIs
StatePublished - Sep 1989

Fingerprint

Lymphokine-Activated Killer Cells
Liver
Liver Neoplasms
Neoplasms
Interleukin-2
Blood Cells
Adoptive Immunotherapy
Adjuvant Chemotherapy
Natural Killer Cells
Plastics
Population

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors. / Schwarz, R. E.; Iwatsuki, S.; Herberman, R. B.; Whiteside, T. L.

In: Cancer Immunology Immunotherapy, Vol. 30, No. 5, 09.1989, p. 312-316.

Research output: Contribution to journalArticle

Schwarz, R. E. ; Iwatsuki, S. ; Herberman, R. B. ; Whiteside, T. L. / Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors. In: Cancer Immunology Immunotherapy. 1989 ; Vol. 30, No. 5. pp. 312-316.
@article{d2c88ca2809a4a1581ab1321a59637ba,
title = "Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors",
abstract = "Adherent lymphokine-activated killer cells (A-LAK cells) obtained from human peripheral blood mononuclear cells represent a population of potent antitumor effectors enriched in interleukin-2(IL-2)-activated natural killer cells. This study shows that A-LAK cells can be successfully generated from the blood of patients with liver cancer not treated with adjuvant chemotherapy or irradiation. Mononuclear cells were isolated from the blood of 33 patients with liver tumors (6 benign, 10 primary malignant, 17 metastatic) at the time of liver resection. A-LAK cells were separated by adherence to plastic following activation of peripheral blood mononuclear cells in 1000 U/ml recombinant IL-2. A-LAK cells (enriched up to 92{\%} in CD3-CD56+ cells) showed better subsequent expansion and two to six times higher antitumor cytotoxicity per cell than unseparated LAK cells cultured under the same conditions. The ability to generate A-LAK cells with superior in vitro cytotoxicity from the blood of most patients with liver cancer indicates that adoptive cellular immunotherapy may be a feasible and new way of treatment for primary and secondary hepatic neoplasms in man.",
author = "Schwarz, {R. E.} and S. Iwatsuki and Herberman, {R. B.} and Whiteside, {T. L.}",
year = "1989",
month = "9",
doi = "10.1007/BF01744900",
language = "English (US)",
volume = "30",
pages = "312--316",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors

AU - Schwarz, R. E.

AU - Iwatsuki, S.

AU - Herberman, R. B.

AU - Whiteside, T. L.

PY - 1989/9

Y1 - 1989/9

N2 - Adherent lymphokine-activated killer cells (A-LAK cells) obtained from human peripheral blood mononuclear cells represent a population of potent antitumor effectors enriched in interleukin-2(IL-2)-activated natural killer cells. This study shows that A-LAK cells can be successfully generated from the blood of patients with liver cancer not treated with adjuvant chemotherapy or irradiation. Mononuclear cells were isolated from the blood of 33 patients with liver tumors (6 benign, 10 primary malignant, 17 metastatic) at the time of liver resection. A-LAK cells were separated by adherence to plastic following activation of peripheral blood mononuclear cells in 1000 U/ml recombinant IL-2. A-LAK cells (enriched up to 92% in CD3-CD56+ cells) showed better subsequent expansion and two to six times higher antitumor cytotoxicity per cell than unseparated LAK cells cultured under the same conditions. The ability to generate A-LAK cells with superior in vitro cytotoxicity from the blood of most patients with liver cancer indicates that adoptive cellular immunotherapy may be a feasible and new way of treatment for primary and secondary hepatic neoplasms in man.

AB - Adherent lymphokine-activated killer cells (A-LAK cells) obtained from human peripheral blood mononuclear cells represent a population of potent antitumor effectors enriched in interleukin-2(IL-2)-activated natural killer cells. This study shows that A-LAK cells can be successfully generated from the blood of patients with liver cancer not treated with adjuvant chemotherapy or irradiation. Mononuclear cells were isolated from the blood of 33 patients with liver tumors (6 benign, 10 primary malignant, 17 metastatic) at the time of liver resection. A-LAK cells were separated by adherence to plastic following activation of peripheral blood mononuclear cells in 1000 U/ml recombinant IL-2. A-LAK cells (enriched up to 92% in CD3-CD56+ cells) showed better subsequent expansion and two to six times higher antitumor cytotoxicity per cell than unseparated LAK cells cultured under the same conditions. The ability to generate A-LAK cells with superior in vitro cytotoxicity from the blood of most patients with liver cancer indicates that adoptive cellular immunotherapy may be a feasible and new way of treatment for primary and secondary hepatic neoplasms in man.

UR - http://www.scopus.com/inward/record.url?scp=0024377343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024377343&partnerID=8YFLogxK

U2 - 10.1007/BF01744900

DO - 10.1007/BF01744900

M3 - Article

C2 - 2624925

AN - SCOPUS:0024377343

VL - 30

SP - 312

EP - 316

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -